Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synovial sarcoma X breakpoint 2 (SSX2), also known as cancer/testis antigen 5.2 (CT5.2) or HOM-MEL-40, is a member of the highly homologous SSX family of nuclear proteins. Under normal physiological conditions, SSX2 expression is highly restricted to the testis (specifically spermatogonia) and is minimally expressed in the thyroid, making it an immune-privileged cancer-testis antigen. However, SSX2 is aberrantly reactivated and overexpressed in a wide variety of malignancies, including synovial sarcoma, melanoma, prostate cancer, pancreatic cancer, breast cancer, and acute myeloid leukemia. In synovial sarcoma, a characteristic t(X;18)(p11.2;q11.2) chromosomal translocation fuses the SS18 gene to SSX2 (or SSX1/SSX4), creating an oncogenic SS18-SSX fusion protein that acts as a transcriptional regulator and drives tumorigenesis.
Due to its highly restricted expression in normal tissues and high immunogenicity in cancer patients, SSX2 is an attractive target for cancer immunotherapy. Therapeutic strategies targeting SSX2 include DNA vaccines (such as pTVG-SSX2), adoptive T-cell therapies (such as the multi-tumor-associated antigen T-cell therapy MT-601), and engineered TCR-T or CAR-T cell therapies. Additionally, epigenetic modifying agents like DNA methyltransferase inhibitors (e.g., decitabine) and histone deacetylase inhibitors (e.g., trichostatin A) are utilized to upregulate SSX2 expression in tumor cells, thereby enhancing their susceptibility to SSX2-targeted immunotherapies.
Adoptive cellular immunotherapy, active immunotherapy, DNA vaccination, DNA methyltransferase inhibition, and histone deacetylase inhibition.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synovial sarcoma X breakpoint 2 (SSX2).